Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The eighth stock on our list of best biotech stocks under $20 is CytomX Therapeutics, Inc.

TheFly reported on January 20 that Piper Sandler raised its price target on CTMX to $10 from $6.50, keeping an Overweight rating. The firm noted that Initial Phase 1 data for varsetatug maseatecan in heavily pretreated metastatic colorectal cancer showed a 28% overall response rate, 94% disease control rate, and 5.8-month median PFS. This quarter, updated data with possible dose-dependent benefits from around 100 patients across three treatment cohorts are anticipated.

Similarly, on the same day, Barclays analyst Etzer Darout also raised the price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $8 from $6 and maintained an Overweight rating. The imminent readout on colorectal cancer was mentioned by the firm as providing an attractive risk-reward profile.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a clinical‑stage biopharmaceutical company that develops Probody therapeutics, condition‑activated antibody prodrugs designed to improve cancer targeting and reduce off‑tumor toxicity. Its pipeline includes innovative immuno‑oncology and targeted therapies aimed at enhancing safety and efficacy for solid tumors and other serious diseases.

While we acknowledge the potential of CTMX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.